These results suggest that PAX8-PPARγ has the potential to be used as a specific marker of the targeted contrast agent for real-time, non-invasive, and early diagnosis of thyroid tumors, and may provide a new theoretical basis and drug target for clinical targeted therapy of thyroid cancer, which has not been reported in the literature at home and abroad, and therefore will promote the further development of thyroid cancer diagnosis and treatment with high basic science and a high practical application value. Here, PAX8 is linked to thyroid gland carcinoma.